The Johns Hopkins University

Mayo Foundation for Medical Education and Research

Buck Institute for Research on Aging

Unity Biotechnology, Inc.

Synthasome Inc.

Other

Massachusetts Institute of Technology

National Institutes of Health, a Component of the US Dept. of Health & Human Services

University System of Maryland

Biomet Manufacturing Corporation

The General Hospital Corporation

University Technology Corporation

National Institutes of Health

Jennifer H Elisseeff

Morgana M Trexler

Marcia W Patchan

Jeffrey P Maranchi

Xiomara Calderon-Colon

Julia B Patrone

Jennifer L Breidenich

Jenna L Graham

Alain Philippe Vasserot

Nathaniel E David

Judith Campisi

Remi-Martin Laberge

Tamar Tchkonia

James L Kirkland

Marco Demaria

Yi Zhu

Albert Davalos

Shimon Unterman

Okhee Jeon

Chaekyu Kim

Anthony Ratcliffe

Dongan Wang

Anirudha Singh

Michael Corvelli

Robert Samuel Langer

Kristi S Anseth

Michael S Yu

Alexander Hillel

Qiongyu Guo

Allen Yi-Lan Wang

Zayna Nahas

Daniel Mulreany

Iossif A Strehin

Hyeseung Janice Lee

Xiao Mo

Derek Sims

Drew M Pardoll

Rocky Sung Chi Tuan

Jan M A Van Deursen

Darren J Baker

Bennett G Childs

Warren L Grayson

Kevin J Yarema

Udayanath Aich

Robert S Langer

Janice Lee

Iwen Wu

Oliver D Schein

Gedge Rosson

Zhaoyang Ye

H Janice Lee

Qiang Li

Ronald Paul Silverman

Frank Huerta

Norman Marcus

Dong-an Wang

Kaitlyn Sadtler

Ben Hung

Ethan Nyberg

Tram Nguyen

Jeannine Coburn

Rocky S Tuan

Jan Ma Van Deursen

Gedge Rossen

Jan MA Van Deursen

Shoumyo Majumdar

The present invention provides novel biomaterial compositions and methods having a technology to improve retention of hyaluronic acid (HA). The biomaterial compositions utilize small HA binding peptides and extracellular matrix binding (ECM) peptides that are tethered to synthetic biocompatible polymers. When tethered to the polymers, the peptide region allows the polymers to bind to HA and to tissues such as cartilage. The novel biomaterial compositions can be used to coat or chemically modify cartilage or tissues with a biologically compatible polymer having HA binding peptides, which allow HA to bind to the surface of the cartilage or tissues. Methods of using same are also provided.

Biomaterials comprising hyaluronic acid binding peptides and extracellular matrix binding peptides for hyaluronic acid retention and tissue engineering applications

An extracellular matrix (ECM) mixture and ECM scaffolds made with same are disclosed. The ECM mixture can comprise from about 5% to about 85% by weight of ECM material and from about 15% to about 95% by weight of a polymer material, such as, but not limited to, a biodegradable polyester. The presently disclosed anatomically-shaped porous ECM scaffolds can be formed, for example, using a three-dimensional (3D) printing process, an injection molding process, or any other process.

Extracellular matrix (ECM) mixture and ECM scaffolds made with same

The present disclosure relates to compositions and methods for modulating wound healing and regeneration. More particularly, the present disclosure relates to immunomodulatory agents that promote wound healing and tissue regeneration, and that may be optionally used in combination with synthetic or biomaterial scaffolds.

Compositions and methods for modulating wound healing and regeneration

The invention provides compositions and methods for the preparation of processed adipose tissue. The invention further provides methods of use of the processed adipose tissue.

Compositions and methods for implantation of processed adipose tissue and processed adipose tissue products

A new class of molecules, C&#x2014;OH tributanoylated hexosamines, including, for example, GalNAc, GlcNAc and ManNAc, are demonstrated to increase cartilage-like tissue accumulation by IL-1&#x3b2;-stimulated chondrocytes. Furthermore, all three molecules reduced NFKB1 and I&#x3ba;B&#x3b1; driven gene expression, consistent with NF&#x3ba;B inhibitory properties of these analogs. GalNAc-a exposure produced the greatest ECM accumulation by IL-1&#x3b2;-stimulated chondrocytes. However, GalNAc-a exposure produced an opposite effect on MSC exposure, where a decrease in ECM accumulation was observed. These findings are in support of the function of NF&#x3ba;B signaling during limb development and growth plate chondrogenesis. The present invention shows the capability of this new class of hexosamine analogs as disease-modifying agents for treating cartilage damage.

Short-chain fatty acid hexosamine analogs and their use in tissue engineering applications

This disclosure provides a technology for managing the sensation of pain in a subject in need thereof. Treatment methods according to this invention include administering to the subject a formulation that contains an effective amount of (4-[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone).

Treatment of joint pain

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2

Treatment for osteoarthritis by intra-articular administration of a cis-imidazoline

Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells

The present invention provides novel biomaterial compositions and methods having a technology to improve retention of hyaluronic acid (HA). The biomaterial compositions utilize small HA binding peptides that is tethered to synthetic biocompatible polymers. When tethered to the polymers, the peptide region allows the polymers to bind to HA. The biocompatible polymers are modified to contain a crosslinking group so that the HA can be incorporated into a scaffold and retained in place. The novel biomaterialcompositions can be made into hydrogel compositions and used in a variety of tissue applications, using mild crosslinking conditions and they also have the ability to be degraded with hyaluronidase if needed. Furthermore, the novel biomaterial compositions will enable enhanced interaction between the scaffold and encapsulated cells for a wide variety of tissue engineering applications. Methods of making hydrogel compositions and their use are also provided. The present invention also provides bifunctional biopolymer compositions comprising a biologically compatible polymer having at least one amine reactive moiety and at least one thiol reactive moiety and provides thiolated HA binding peptides which can be used together to coat or chemically modify cartilage or tissues having amine reactive residues with a biologically compatible polymer having HA binding peptides, which allow HA to bind to the surface of the cartilage or tissues. Methods of using same are also provided.

Biomaterials comprising hyaluronic acid binding peptides and bifunctional biopolymer molecules for hyaluronic acid retention and tissue engineering applications

The present invention provides cellulose hydrogels having one or more of the following properties: high water content, high transparency, high oxygen permeability, high biocompatibility, high tensile strength and desirable thermal stability. The present invention further provides a process for preparing a cellulose hydrogel comprising (i) a step of activating cellulose, in which the activating step comprises contacting the cellulose with a solvent to activate the cellulose for a time duration from about 2 hours to about 30 hours; (ii) substantially dissolving the activated cellulose to form a solution; and (iii) gelling the solution to form a gel, in which the gelling step comprises allowing the solution to gel in an environment comprising a relative humidity from about 30% to about 80% at 35&#xb0; C.

Cellulose hydrogel compositions and contact lenses for corneal applications

The invention provides compositions and methods for the preparation of biocompatible biomaterials from adipose tissue. Biocompatible biomaterials are cellular or acellular biomaterials. The invention further provides methods of use of the biocompatible biomaterials.

Compositions and methods for implantation of adipose tissue and adipose tissue products

The present invention provides a wound healing composition comprising a biocompatible hydrogel membrane wherein the hydrogel membrane has one or more of the following properties: high water content, high transparency, high permeability, high biocompatibility, high tensile strength and an optimal thickness. The invention further provides methods of treating a wound in a subject in need thereof, comprising contacting the wound with a biocompatible cellulose hydrogel membrane of the invention.

Wound healing compositions comprising biocompatible cellulose hydrogel membranes and methods of use thereof

Growing community of inventors

Los Angeles, CA, United States of America

Jennifer H Elisseeff